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Ribonucleotide reductase (RNR) is an enzyme involved in the de novo synthesis of 
deoxyribonucleotides, which are critical for DNA replication and DNA repair. Triapine is a 
small-molecule RNR inhibitor. A phase I trial studied the safety of triapine in combination 
with cisplatin–paclitaxel in patients with advanced stage or metastatic solid tumor can-
cers in an effort to capitalize on disrupted DNA damage repair. A total of 13 patients with 
various previously treated cancers were given a 96-h continuous intravenous (i.v.) infu-
sion of triapine (40–120 mg/m2) on day 1, and then 3-h i.v. paclitaxel (80 mg/m2) followed 
by 1-h i.v. cisplatin (50–75 mg/m2) on day 3. This combination regimen was repeated 
every 21 days. The maximum tolerated dose (MTD) for each agent was identified to be 
triapine (80 mg/m2), cisplatin (50 mg/m2), and paclitaxel (80 mg/m2). Common grade 3 
or 4 toxicities included reversible anemia, leukopenia, thrombocytopenia, or electrolyte 
abnormalities. The combination regimen of triapine–cisplatin–paclitaxel resulted in no 
objective responses; however, five (83%) of six patients treated at the MTD had stable 
disease between 1 and 8 months duration. This phase I study showed that the combi-
nation regimen of triapine–cisplatin–paclitaxel was safe and provides a rational basis for 
a follow-up phase II trial to evaluate efficacy and progression-free survival in women with 
metastatic or recurrent uterine cervix cancer.
Keywords: triapine, cisplatin, paclitaxel, phase i clinical trial, cancer, maximum tolerated dose, cervical cancer, 
uterine cervix cancer
inTrODUCTiOn
Uterine cervix cancers are aggressive gynecological malignancies marked by abdominopelvic 
lymph node or visceral organ metastases and by poor metastatic disease-specific survival, and 
up to 80% have been shown to overexpress ribonucleotide reductase (RNR) (1–4). Women with 
recurrent uterine cervix cancer treated by first-line cisplatin–paclitaxel combination chemo-
therapy have disease response (46%) more often than other cisplatin–non-platinum combina-
tions (12–31%) (5–9). Adding the humanized vascular endothelial growth factor-neutralizing 
monoclonal antibody bevacizumab to cisplatin–paclitaxel chemotherapy in the same setting 
resulted in higher disease response (50%) and a median survival of 18 months (4). However, no 
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curative therapy exists for women with metastatic uterine cervix 
cancer, and therefore, these women have a significant unmet 
therapeutic need.
Based on knowledge of cell cycle controlled expression 
and activity of RNR, there was, until recently, a fairly simple 
understanding of the molecular behavior of cancers harboring 
unchecked RNR like those of the uterine cervix. In dormant (G0-
phase) or resting (G1-phase) cells, when levels of RNR subunit 
proteins are low, enzyme activity, and therefore nucleotide out-
put, is minimal (10). In replicating cells (S–G2-phase) like cancer 
cells, when RNR subunit proteins are expressed at elevated levels, 
enzyme activity and nucleotide output are maximal—ultimately 
regulated by inherent feedback allosteric sites in RNR and not 
necessarily by levels of enzyme subunit expression (11). The 
allosteric activity site detects the overall nucleotide concentration 
and balances de novo nucleotide production (12). When RNR 
activity is high, DNA damage repair is timely, facile, and impacts 
downstream cell fate decisions that are prosurvival rather than 
lethal (13–18). Expansion of nucleotide pools during DNA 
damage has a clear physiological role, and it has been shown that 
increased nucleotide concentrations as outputs from RNR help 
cells survive DNA damage (19). Such findings provide a strong 
rationale for clinical development of new agents that exploit RNR 
repair and DNA damage responses, especially in cancers with 
unchecked RNR. Triapine (also known as 3-aminopyridine-
2-carboxaldehyde thiosemicarbazone or 3-AP) is a potent 
inhibitor of RNR with known antiproliferative and cytotoxic 
effects (13–18). In preclinical studies of uterine cervix cancer 
cells, triapine potently blocks deoxynucleotide output by RNR 
after DNA damage, protracts cell cycle arrest at the G1–S-phase 
checkpoint, and leads to unresolved γH2AX foci (i.e., phospho-
rylated histones flanking DNA double-strand breaks) marking 
DNA damage (13–15)—all disruptive to normal RNR functions 
(Figure 1).
Early phase I studies of triapine alone and in combination 
in patients with metastatic and advanced stage cancers have 
shown intermittent triapine to have relatively mild toxicity, but 
continuous intravenous (i.v.) infusion triapine reaches a maxi-
mum tolerated dose (MTD) in terms of drug-related toxicities 
(20–25). Thus, this phase I trial was designed to evaluate whether 
continuous i.v. infusion triapine could inhibit RNR and potenti-
ate the antitumor effects of cisplatin–paclitaxel with acceptable 
toxicity levels in patients with metastatic or advanced stage 
solid tumor cancers refractory to standard therapy or for which 
no curative therapy existed (http://clinicaltrials.gov number, 
NCT00016874).
MaTErialS anD METHODS
Study Design and Treatment
VION-015 was an open-label dose-finding trial of i.v. triapine–
cisplatin–paclitaxel chemotherapy (Table  1). Patients were 
enrolled according to a dose escalation schema using a stand-
ard Fibonacci 3 +  3 patient cohort phase I trial design. This 
trial’s design declared a single drug-related adverse event in a 
three-patient cohort as an event to prompt an additional three 
patients being accrued (i.e., six patients in the dose level cohort) 
for confirmation of a 33% rate of attributable toxicity. Accrual 
continued if no other adverse events were observed (i.e., two or 
fewer of six patients in the dose level cohort); otherwise, accrual 
discontinued. The MTD was established when six patients had 
been treated with less than or equal to one toxic event. Adverse 
events were scored in this trial according to the Common 
Terminology Criteria for Adverse Events (version 2.0), which was 
the criteria used at-the-time this study was conducted. Adverse 
events indicating dose-limiting toxicity included all severe or 
life-threatening toxicities, grade 3 non-hematologic toxicities, 
grade 4 neutropenia lasting more than 3 days or associated with 
infection, grade 4 thrombocytopenia lasting more than 3  days 
or associated with clinically significant bleeding, or persistent 
adverse events of any grade requiring delay of scheduled treat-
ment by more than 2 weeks.
Patients were administered i.v. triapine by 96-h continu-
ous infusion at an initial dose of 40 mg/m2 starting on day 1 
(Table 1). Triapine infusions were repeated every 21 days. Vion 
Pharmaceuticals supplied i.v. triapine in 50 mg viscous liquid 
vials, which were diluted for an ambulatory continuous infu-
sion pump per the manufacturer’s instruction. Administration 
and i.v. bag sets were exchanged fresh after every 48  h of 
infusion.
Patients received i.v. paclitaxel over 3 h at a single fixed dose 
of 80 mg/m2 starting on day 3 (Table 1). Commercial paclitaxel 
was diluted for infusion per the manufacturer’s instruction. 
Participants received i.v. cisplatin over 1 h between 50 and 75 mg/
m2 starting on day 3 (Table  1). Commercial cisplatin also was 
diluted for infusion per the manufacturer’s instruction. In this 
particular trial, paclitaxel infusion preceded cisplatin infusion. 
Cisplatin and paclitaxel administrations were also repeated every 
21 days.
By definition for this trial, two courses of triapine–cisplatin–
paclitaxel constituted one cycle of therapy. Patients were eligible 
to receive a second or subsequent cycle of therapy if they had 
stable disease or, a partial or complete response.
Eligibility and Enrollment
The trial was open to women and men 18 years of age or older 
with a diagnosis of a measurable metastatic or advanced stage 
cancer refractory to one or more standard therapies or for which 
no curative therapy existed. Patients must have had an Eastern 
Cooperative Oncology Group performance status score of 0 or 
1; a life expectancy greater than 3 months; adequate kidney, liver, 
and bone marrow function as determined by laboratory assess-
ment; and must have been practicing adequate contraception or 
abstinence. Female patients of childbearing potential must have 
had a negative pregnancy test within 2 weeks before study drug 
administration. Patients must not have had active heart disease, 
moderate-to-severe compromise of pulmonary function, active 
infections, severe hearing impairment or grade 2 or higher 
neuropathy, active central nervous system metastases, presence 
of any other life-threatening illness, prior severe allergic reaction 
to study agents, or presence of any active bleeding or coagula-
tion disorder. Patients must have had prior treatment for their 
cancer, had at least 3 weeks of recovery from prior surgery, last 
dose of chemotherapy, and/or last dose of radiotherapy. Persistent 
TaBlE 1 | Dose escalation and extent of drug exposure.
Dose level Triapine dose  
(mg/m2/day)
Paclitaxel dose  
(mg/m2)
Cisplatin dose  
(mg/m2)
no. of new 
patients
Total no. of patients 
treateda
Total no. course 
administered
Triapine day 1 and paclitaxel–cisplatin day 3 q3-week schedule (n = 11)
1 40 80 50 4 5 14
2 80 80 50 6 7 26
3 80 80 75 1 1 1
Triapine day 1 and paclitaxel–cisplatin day 3 q3-week schedule (n = 2)b
−2 40 80 50 0 0 0
−1 80 80 50 0 0 0
1 120 80 50 2 2 2
aSome patients were treated at more than one dose level.
bThe protocol was amended to introduce a fixed starting dosing of paclitaxel and cisplatin.
FiGUrE 1 | Besides its classical role in nuclear Dna replication, rnr has diverse functions in other biological processes, including mitochondrial 
Dna replication, cell cycle regulation, Dna damage repair, and apoptosis. RNR acts as the primary de novo reductase supplying on-demand dNDP DNA 
precursor pools. In this role, RNR rate limits nuclear and mitochondrial DNA replication. Its payouts are tightly regulated by allosteric feedback (apoptosis effects), by 
S-phase-dependent M2 subunit expression (cell cycle arrest effects), and by p53 protein–M2b subunit interactions (DNA repair effects). The RNR catalytic 
mechanism involves a proton-coupled electron transfer, relocating iron-stabilized tyrosyl radicals housed in its small M2 or M2b subunits to radical-based catalytic 
sites in its large M1 subunits. Pharmacological disruption of the M2 or M2b iron–metal moieties by triapine is sufficient to render RNR inactive. Abbreviations: RNR, 
ribonucleotide reductase; mtDNA, mitochondrial DNA; BER, base excision repair, NER, nucleotide excision repair; MMR, mismatch repair; HR, homologous 
recombination; DSB, double-strand brake; dNDP, deoxynucleotide diphosphates.
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toxicities from prior treatments must not have been greater than 
grade 1. Patients who had received cisplatin or paclitaxel indi-
vidually, but not in combination, were eligible. Patients who had 
received cisplatin–paclitaxel must not have had the pair within 
the previous 6 months before planned study entry. Patients whose 
prior therapy included triapine were eligible.
assessments
Medical histories, physical examinations including performance 
status assessment, urinalysis, and laboratory studies, including 
serum chemistries and complete blood counts were obtained at 
baseline, before the first dose of each 96-h triapine cycle, once 
each interval week, and at off-study. Chest radiograph, computed 
tomography scans of the chest and abdomen (excluding pelvis), 
and serum tumor markers (i.e., CA-125, CA19-9, CEA) were 
obtained every two cycles. Magnetic resonance imaging of the 
brain or bone scan was obtained every two cycles, as clinically 
indicated for a patient’s disease and status.
Study Oversight
The principal investigators (Della Makower, Andreas Kaubisch, 
and Mario Sznol) designed the clinical trial and the dose escala-
tion/dose reduction schema. Vion Pharmaceuticals, the sponsor 
of the study, supplied triapine and collected all the clinical data, 
TaBlE 2 | Patient and disease characteristics (n = 13).











Black or African-American 3 23









Uterine cervix 2 15
Bladder 1 8
Bile duct 1 8
Esophageal 1 8
Gastric 1 8
Pyriform sinus 1 8
Small intestine 1 8
Tonsil 1 8
Adenocarcinoma, not specified 1 8
No., number.
aMay not total 100% due to rounding.
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but did not participate in the study design, analysis, or manuscript 
preparation. An independent quality assurance audit (Prologue 
Research International) documented in compliance with all 
applicable regulations during the trial period. All participating 
sites received institutional review board approval prior to first 
dose infusion. A manuscript publication team (Charles A. Kunos, 
Edward Chu, and Susan Percy Ivy) subsequently reviewed, col-
lated, authenticated, and analyzed the trial data for manuscript 
publication.
Evaluation of Clinical activity and 
Statistical analysis
Response Evaluation Criteria in Solid Tumors (version 1.0) were 
applied at baseline and every two treatment cycles for response 




Patients were eligible for this phase I study from April 2001 
through December 2002. A total of 13 patients were enrolled 
to receive triapine–cisplatin–paclitaxel, and all patients were 
evaluated with regard to safety. Baseline patient characteristics 
are listed in Table 1. All patients underwent previous treatment 
for their advanced stage or metastatic cancer, including surgery 
(n = 6), cytotoxic chemotherapy (n = 8), or palliative radiation 
therapy (n = 4). None of the enrolled patients had prior hormonal 
therapy or immunotherapy. As seen in Table  2, three different 
dose levels were evaluated.
Safety
Table 3 lists the most common toxicities observed in all three 
dose levels of the study. The most frequent adverse events 
included grade 1 constipation, nausea, or emesis; grade 2 
fatigue; grade 3 thrombocytopenia; and reversible grade 3 or 4 
anemia (10 [77%] of 13) and leukopenia (8 [62%] of 13). The 
hematologic toxicity observed in one participant with uterine 
cervical cancer at the 80  mg/m2 dose of triapine, 75  mg/m2 
dose of cisplatin, and 80  mg/m2 dose of paclitaxel prompted 
enrollment of the next three patients to the next lower dose 
level. This also led to an amendment of the protocol for an 
escalated triapine dose preceding a fixed dose of cisplatin and 
paclitaxel (Table 2). The triapine (80 mg/m2)–cisplatin (50 mg/
m2)–paclitaxel (80 mg/m2) dose level was declared the MTD. 
In six patients treated at the MTD, the attributed grade 3 or 4 
toxicity rate was 50% with the main side effects being revers-
ible fatigue, hyperbilirubinemia, anemia, leukopenia, and 
thrombocytopenia.
Dose reductions of triapine occurred in two patients (15%) 
after the first course of treatment. There were no dose reductions 
of cisplatin or paclitaxel. Three patients (23%) discontinued 
therapy after the first course of treatment. The reasons for 
treatment discontinuation included skin toxicity in the form 
of Stevens–Johnson syndrome in one patient, physician prefer-
ence in one patient, and patient preference in one patient. The 
median number of treatment cycles was 3 (range, 1–9 courses). 
No treatment-related deaths occurred while on study. A fatal 
adverse event occurred in one (8%) patient, with this event being 
attributed to disease progression within 30 days after receipt of 
study treatment.
Efficacy
For patients who received at least two courses of therapy (i.e., 
one cycle), no objective responses were observed. Stable disease 
occurred in six (46%) patients. The durations of stable disease 
response were 1, 2, 2, 5, 7, and 8 months. In the MTD cohort, 
five patients (of six, 83%) best responses of stable disease were 
observed. One patient in the MTD cohort had metastatic uterine 
cervix cancer, and her disease response was determined to be 
approximately 30% after three therapy cycles (i.e., seven 21-day 
infusion courses). Her stable disease response lasted 8 months. 
Progression of disease was recorded in five (38%) patients at 
initial response assessment. In one (8%) patient with uterine 
cervix cancer enrolled at the triapine (80  mg/m2)–cisplatin 
(75  mg/m2)–paclitaxel (80  mg/m2) dose level, symptomatic 
decline did not permit documentation of disease status, and 
thus, this patient was listed arbitrarily as having had clinical dis-
ease progression. Response was not evaluated after study entry 
in one (8%) patient. Serum tumor marker responses appear in 
Figure 2.
TaBlE 3 | adverse events by grade with any relationship to triapine–
paclitaxel–cisplatin (n = 13).a
Grade
1 2 3 4 5
Toxicity no. no. no. no. no.
Allergy/immunology 0 0 0 1 0
Blood/bone marrow (other) 0 3 0 0 0
 Anemia 0 1 7 3 0
 Febrile neutropenia 0 0 0 0 0
 Leukopenia 1 0 2 6 0
 Thrombocytopenia 0 1 5 0 0
Cardiovascular 5 0 2 0 0
Constitutional (other) 15 12 4 0 0
 Fatigue 5 6 2 1 0
Dermatology/skin 11 3 1 0 0
Endocrine/special senses (other) 4 3 0 0 0
 Tinnitus 0 0 0 0 0
 Hearing Loss 1 0 0 0 0
Gastrointestinal (other) 16 2 0 0 0
 Constipation 6 2 0 0 0
 Diarrhea 4 3 0 0 0
 Emesis 6 3 3 0 0
 Nausea 6 4 2 0 0
Infection 0 0 2 0 0
Metabolic/nutritional 19 6 6 1 0
 Creatinine increased 0 0 0 0 0
 Hypokalemia 4 0 1 1 0
 Hyponatremia 0 0 1 0 0
Musculoskeletal 1 0 0 0 0
Neurology 11 8 1 0 0
Respiratory system (other) 11 1 0 0 0
 Dyspnea 1 1 1 0 0
 Hypoxia 0 0 1 0 0
 Pulmonary embolus 0 0 0 1 0
Renal/genitourinary 2 2 1 0 0
Sexual/reproductive function 0 0 0 0 0
Worst non-hematologic 128 56 28 5 0
Worst hematologic 1 5 14 9 0
No., number.
aPatients may have had more than one adverse event.
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DiSCUSSiOn
This phase I trial found that triapine–cisplatin–paclitaxel was 
a safe therapeutic option for patients with previously treated 
advanced stage or metastatic solid tumor cancers. Patients treated 
using triapine–cisplatin–paclitaxel most often reached a stable 
disease status, consistent with at-the-time known preclinical (18) 
and clinical data (20–22) among a broad spectrum of molecularly 
driven cancer phenotypes, and not just uterine cervix cancers.
In this trial, there was an elevated rate of grade 3 or 4 anemia 
(77%) after triapine–cisplatin–paclitaxel, possibly as a result of 
potent iron chelation by triapine (27) without interference in 
total iron binding capacity (22). This rate of anemia was not 
observed in contemporary cisplatin–paclitaxel trials [18–25% 
(5, 28)]. Patients who received triapine–cisplatin–paclitaxel 
had a similar incidence of grade 3 or 4 leukopenia (62%) in the 
context of another cisplatin–paclitaxel trial [64% (5)].
Until the results of triapine–cisplatin–radiation trials were 
reported (23–25), non-randomized early phase trials provided the 
best evidence base for RNR inhibition by triapine before cytotoxic 
chemotherapy (29–32). An assumption made in the 90s was that 
cancer cells gained from overproduced RNR or from overactive 
RNR from relaxed allosteric regulation (33), and that sustained 
pharmacological blockade of RNR would kill cancer cells (18). Two 
trials involved continuous infusion triapine infusion for sustained 
RNR inhibition, and unfortunately, yielded no partial or complete 
disease responses by standard criteria (21, 22). Other triapine-agent 
combination trials scheduling triapine before cytotoxic chemo-
therapy also resulted in few (8 [9%] of 88 participants) disease 
responses (29–32). This trial of triapine before cisplatin–paclitaxel 
also found no partial or complete disease responses by standard 
measurement criteria or by serum tumor markers (when avail-
able). Later preclinical data found that triapine scheduled before 
cytotoxic agents blocks overall RNR activity for cytostatic effect, 
stimulates overproduction of RNR for restored activity 18–24 h 
later, facilitates DNA repair, and ultimately may be prosurvival in 
effect (32). Another discovery that the highly electrophilic plati-
num ion (Pt3+) rapidly depletes the concentration of free triapine 
over a long incubation period in cell-free medium (34), thereby 
attenuating triapine’s RNR-blocking activity, cautions sequencing 
triapine before cisplatin–paclitaxel. But for the converse sequence, 
triapine given after DNA-damaging cisplatin or radiation inhibits 
overall RNR activity for cytotoxic effect, halts nucleotide supply 
by RNR when most vital to repair of damaged DNA, protracts 
DNA repair, and therefore, is highly cytotoxic (13–15, 32). As an 
example, triapine–cisplatin–radiation trials show a 96% disease 
response rate (23–25). Thus, protracted nucleotide demand (e.g., 
by damaging DNA) unmet by nucleotide supply (e.g., by inhibit-
ing RNR) becomes intolerable and cell death occurs. Sequencing 
effects of triapine–paclitaxel on the mitotic spindle and late cell 
cycle-phase nucleotide demands have not been explored and war-
rant further preclinical study.
Interpretative limitations for this trial include accrual of few 
participants, lowering an ability to assess safety and therapeutic 
response in disease-specific subgroups such as women with 
metastatic uterine cervix cancer, infrequent biomarker collection 
to inform response efficacy, potential investigator bias due to 
relatively arbitrary changes in triapine–cisplatin–paclitaxel trial 
logistics following observed toxicity, and recall bias due to a very 
delayed time from trial closure to trial publication.
In summary, this phase I trial provides evidence that the 
combination of the RNR inhibitor triapine and the cytotoxic 
chemotherapies cisplatin and paclitaxel may be given together 
safely in patients with metastatic or advanced stage solid tumor 
cancers. Future studies should consider the use of oral triapine for 
RNR blockade optimally integrated into a second-line cisplatin–
paclitaxel chemotherapy regimen for women with metastatic 
uterine cervix cancer.
ETHiCS STaTEMEnT
This study was carried out in accordance with the recommenda-
tions of the Montefiore Medical Center and of the Weill Cornell 
Medical College with written informed consent from all subjects. 
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by the 
AB
C
FiGUrE 2 | Triapine–cisplatin–paclitaxel induces mixed biomarker responses in patients with metastatic or advanced stage solid tumor cancers 
refractory to standard therapy or for which no curative therapy existed. Shown are the biomarker levels (assessed as the longest linear dimension) over time 
for CA-125 (a), CA19-9 (B), and CEA (C). Circles mark the posttherapy time point at which biomarker assessment was obtained. CA-125, CA19-9, and CEA did 
not associate with the pattern or duration of response. Abbreviations: CA-125, cancer antigen-125; CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen.
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Institutional Review Boards of the Montefiore Medical Center 
and of the Weill Cornell Medical College.
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